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ABSTRACT
Context: Medicaid managed care network adequacy standards vary widely across states and are
not typically informed by scientific evidence. The comparative efficacy of these standards for
protecting the health of the Medicaid population has not yet been comprehensively researched.
Objective: The aims of this study are to construct simulation modeling methods to approach this
policy problem and to determine which numeric values for network adequacy standards are most
effective for producing favorable health outcomes for Medicaid recipients who develop CVD.
Design and Setting: A continuous-time Markov model was used to simulate the natural history
of cardiovascular disease, using a cohort that is representative of the Medicaid population over
40, under different provider appointment wait times and CVD emergency travel time delays.
Input and Output Measures: Medicaid claims data from Tennessee in 2019, Social Security
life expectancy data, the Centers for Disease Control and Prevention's Wide-ranging Online Data
for Epidemiologic Research (CDC WONDER) database, and values pulled from existing
literature were used to inform input parameters. Survival time, age at death, number of lifetime
hospital visits, number of lifetime provider visits, time spent in recovery, time spent waiting for
an appointment, lifetime healthcare costs, and lifetime healthcare costs attributable to
hospitalization were collected as simulation outputs.
Results: It was found that the strategy with a 45-day appointment wait time and 0-minute
emergency travel time delay yielded the most favorable health outcomes for individuals with
CVD: mean age at death of 83.79 (83.10, 84.47) and mean survival time of 32.08 (31.09, 33.07).
When the strategies hypothesized to be the “best” (7-day wait times and no travel delay) and
“worst” (90-day wait times and 90-min travel delay for emergencies) were run in comparison to
2

one another, statistically significant differences were found for time spent in recovery, time spent
waiting for an appointment, provider visit quantity, and healthcare system cost burden.
Statistically significant differences were not found for life expectancy, hospital visit quantity,
and costs attributable to hospitalization.
Conclusion: There is not enough evidence of robustness in these results to recommend that
policy decisions should be made using them; further complexities and calibration should be
incorporated into the model before doing so.
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INTRODUCTION
Background
Network adequacy standards are quantitative requirements put in place by state
governments to ensure that the provider networks created by Medicaid managed care
organizations (MCO) provide sufficient access to care for the populations served.1 These
standards specify the minimum quantity of providers, healthcare facilities, and appointments in
an area and set requirements for their availability to Medicaid MCO recipients. Narrow-network
health plans, which are typically defined as plans where less than a quarter of the physicians in a
locality participate, are frequently used as cost containment strategies in Medicaid managed care
and constrain choice2—despite evidence that these plans make it more difficult for patients to
access care.3 Robust network adequacy standards could be leveraged to protect and enhance a
recipients’ ability to receive care from a provider or healthcare facility by setting a floor on how
restrictive these networks can be. Although the federal government requires that states practice
transparency and make these standards available online to all, 4 it is incredibly difficult to locate
these documents. The most recent compilations of standards across U.S. states were created by
the Department of Health and Human Services in 20145, the National Conference of State
Legislatures in 20186, and the Legal Action Center in March 2020.7
In the past, states were required to use travel time and distance, at a minimum, as
standards for assessing provider network adequacy. 8 In November 2020, the Centers for
Medicare and Medicaid Services removed this requirement to accommodate for growth in
telehealth.9 States are now given the flexibility to choose to use one or more of the following
standards or other quantitative measures 10: geographic criteria (e.g. travel time, travel distance),
appointment access (e.g. appointment wait time, hours of operation for a provider), and provider
8

characteristics (e.g. provider-to-enrollee ratio, providers accepting new patients). The Legal
Action Center reports that twenty-six states have adopted geographic standards, seventeen states
have adopted appointment wait time standards, and thirteen states have adopted provider
characteristic standards. 11
For geographic criteria, both travel time (maximum number of minutes it takes for a
patient to travel from their residence to their provider’s location) and travel distance (maximum
number of miles a patient must travel from their residence to their provider’s location) are
typically defined. Across states, these standards range from 30-120 minutes and 5-75 miles
depending on rurality and the health service being sought. As maximum time and distance limits
increase, individuals have a harder time accessing care. There is some evidence that an increase
in time and distance to a healthcare provider is associated with a decay in health outcomes. 12
Medicaid serves the low-income population—individuals who are less likely to have disposable
time and income to allocate towards travel—increased geographic criteria could serve as a
potential deterrent for care seekers. This network adequacy standard is represented in this model
in the form of 0-, 30-, or 90-minute delays in getting to a hospital, with the assumption that these
delays impact the survival rate from a hospitalization due to a cardiovascular event.
For appointment access, appointment wait time (maximum number of business days a
patient must wait for an appointment with a provider after requesting a medically necessary
service) or hours of operation for a provider (minimum hours a provider’s practice is open during
a week including extended or weekend hours) are typically defined. Across states, these
standards vary depending on the type of care needed and the setting where that care is
administered. Urgent and emergency care is often required to be accessible within 0-96 hours for
24 hours per day and 7 days a week. Appointment access standards for primary care range from
9

7-90 calendar days and some states require primary care providers to keep their offices open for
at least 20 hours per week. Scenarios were modeled under which individuals wait 7, 45, or 90
days for an appointment with a primary care provider or a cardiologist.
For provider characteristics, Provider-to-Enrollee ratios (maximum number of enrollees a
plan may have per available provider) or the minimum percentage of providers in a plan that are
actively accepting new patients are typically included. Larger Provider-to-Enrollee ratios are
expected to give patients less scheduling difficulty when seeking care and receive more
personalized attention from their provider. The simplifying assumptions made for this model’s
structure prevent provider characteristic network adequacy standards from adequate
incorporation into the simulation.
This simulation model will assess how different network adequacy standard strategies
impact lifespan, care access, and economic burden of Medicaid recipients who develop
cardiovascular disease (CVD). CVD is the leading cause of death globally 13 and prevalence rates
are disproportionately higher in low-income populations14—the population served by Medicaid.
As a disease that requires high frequency of management and intervention, it is plausible that
changing Medicaid network design standards, thus affecting how low-income CVD patients
access and utilize care, would ultimately have an impact on population health outcomes.
Aims and Hypotheses
The aims of this study are to construct simulation modeling methods to approach this
policy problem and determine which numeric values for appointment wait time and travel time
delay network adequacy standards are most effective for protecting the health of Medicaid MCO
recipients who develop CVD. For the purposes of this project, life expectancy is considered the
10

most important performance indicator; the “best” strategy will be the one that yields the largest
mean survival time and oldest mean age at death for those who eventually die of CVD-related
causes.
It is expected that maximum access to care for individuals with CVD will occur under the
shortest appointment wait time and smallest travel time to a hospital. There is a well-established
connection between health service access and population health outcomes.15 Therefore, the
strictest network adequacy standards, “Short” appointment wait time (7 day wait) and “None”
travel time delay (0 min delay), should in combination produce the most favorable health
outcomes. This strategy would be expected to produce the largest survival time for those who die
of non-CVD causes, longest amount of time spent in recovery, shortest amount of time spent
waiting for an appointment, greatest percent of individuals who die in recovery, and the highest
burden on the healthcare system (hospital visits, provider visits, and Medicaid costs).

METHODS
Model Structure and Assumptions
A continuous-time Markov model was used to simulate cardiovascular disease health and
outcomes in Medicaid recipients older than age 40 under different network adequacy standard
strategies. The cohort was initialized at the start of the simulation to represent the age and gender
distribution of the Medicaid population. The simulation settings include: a cohort population size
of 10,000 people, a simulation length of 150 years, a significance level for calculating
confidence intervals of 0.05, and an annual discount rate of 0.03. The program was written using
Version 3.9 of the Python programming language and employs the Simulation in Medicine
(SimPy) library to support analyses and operations.16, 17
11

At the start of the simulation, all patients are assumed to be healthy and with no
symptoms or history of CVD. The stochastic simulation method used in this model, the Gillespie
algorithm18, continuously determines which state a patient will progress to next and at what time
point in the future that progression will occur. The Gillespie algorithm calculates this movement
using transition rates specific to the age and gender of the individual in the cohort being
simulated. Figure 1 depicts the eight states included in this model and how individuals flow
between these states.
FIGURE 1. SCHEMATIC OUTLINE OF MODEL STRUCTURE

The natural history of cardiovascular disease is simplified significantly for the purposes
of this model. Individuals can only exist in the following states (defined in Table 1): Well,
Hospitalized, CVD Death, Waiting for Appointment (“Silent” CVD), Waiting for Appointment
(Post-Emergency), Short-Term Post Hospitalization Recovery, Long-Term CVD Management,
Background Mortality.
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TABLE 1. DESCRIPTION OF MODEL STATES

State

Description

Well

Medicaid recipients with no CVD-related symptoms.

Waiting for Appointment
(“Silent” CVD)

Individual has requested a visit with a PCP or Cardiologist
after experiencing CVD symptoms or for regular checkups
while managing their CVD long term. Movement out of this
state into a recovery state indicates the completion of a visit.

Waiting for Appointment
(Post Emergency)

Individual has requested a visit with a PCP or Cardiologist
during or after post hospitalization recovery. Movement out of
this state into a recovery state indicates the completion of a
visit.

Hospitalized

Patient is receiving emergency care (for a heart attack, heart
failure, stroke, etc.) or surgery.

Short-Term Post
Hospitalization Recovery

Individual is managing post-hospitalization health status
through a prescribed treatment regimen (medication, specific
behaviors, etc.).

Long-Term CVD
Management

Individual is managing current health status through a
prescribed treatment regimen (medication, specific behaviors,
etc.). It is assumed that the patient will revisit this state after
CVD events and checkups until death.

CVD Death

Death after hospitalization or treatment in recovery for CVDrelated causes

Background Mortality

Death due to non-CVD-related causes

An individual who develops CVD in this model is assumed to have done so through one
of two pathways: sudden cardiac emergency or “silent” CVD. In the sudden cardiac emergency
pathway, a well individual experiences the onset of sudden AMI or stroke and is then
hospitalized. This hospitalized patient will then either die from CVD-related causes or be moved
to short-term post-hospitalization recovery. In this short-term recovery stage, an individual is
managing post-hospitalization health status through a prescribed treatment regimen. They may
then be readmitted to the hospital due to sudden onset emergency or the presentation of
13

symptoms. Otherwise, they will wait for an appointment with a PCP or Cardiologist where they
are prescribed a treatment regimen to manage their health status in the long term. This health
status will be sustained, with frequent transitions to the Waiting for Appointment state and back
to simulate check-ups with a provider, until hospitalization readmission or death occurs. Those
who are recovering in short-term post-hospitalization and those waiting for a post-emergency
appointment are at an elevated risk of CVD death.
In the “silent” CVD pathway, a well individual notices symptoms of cardiovascular
disease (angina, heart arrythmia, and other risk factors of CVD) and schedules an appointment
with a provider. As they are waiting for an appointment, they may experience a CVD death from
their symptoms or become hospitalized. If the wait time elapses without either scenario
occurring, the individual is prescribed a treatment regimen and moves to the long-term CVD
management state. Individuals can die from non-CVD causes (background mortality) in any
model state.
Model Inputs – Transition Rate Parameters
This model’s parameters were informed by Medicaid claims data, Social Security life
expectancy data, the CDC WONDER database, and values pulled from existing literature.
Detailed eligibility, enrollment, inpatient, outpatient, and pharmaceutical claims for Medicaid
managed care beneficiaries in Tennessee were used to inform age and gender demographics,
prevalence of CVD, hospital admission and readmission rates, and provider visit rates. Social
Security Administration and CDC WONDER data were used to inform the background mortality
rate and CVD death rates in and out of a medical facility setting. Parameters were calculated,
partitioned by gender, for five-year age groups beginning at age 40 and ending at 100+.
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Table 2 outlines the calculations done to obtain the mortality rates used to inform the
model parameters. Background mortality was calculated by subtracting annual cardiovascular
disease mortality rates from all-cause mortality rates. Annual all-cause mortality rates were
pulled from the Social Security Administration’s 2019 Period Life Table; each five-year
age/gender group is represented by the death probability value corresponding to the median age
of the group.19 Crude CVD-related mortality rates were taken directly from the CDC WONDER
dataset for the ages 40-84 in 2019.20 Due to the unavailability of population counts, the CDC
WONDER data request was unable to return crude rates per 100,000 for the 85 and older
population. These age groups were assumed to have the same CVD-related mortality rates as the
80-84 age group.
This model assumes that individuals who develop CVD will either have a low or high
risk of CVD-related death, depending on which state they are in. Those who are Waiting for
Appointment (“Silent” CVD) or Long-Term CVD Management are subjected to the low-risk
mortality parameters. Those who are Hospitalized, Waiting for Appointment (Post Emergency),
or Short-Term Post Hospitalization Recovery are subjected to the high-risk mortality parameters.
For the purposes of this model, a CVD death is classified as one that is marked with one or more
of the ICD-10 Codes I00-I99 (Diseases of the circulatory system) in 2019 in the CDC WONDER
dataset. CVD deaths that occurred in a medical facility (marked as Medical Facility – Inpatient,
Medical Facility - Outpatient or ER, Medical Facility - Dead on Arrival, Medical Facility –
Status unknown) were considered high-risk deaths.21 CVD deaths that occurred outside of a
medical facility (marked as Decedent's home, Hospice facility, Nursing home/long term care,
Other, Place of death unknown) were considered low-risk deaths.22 The final transition rates
were determined by dividing the crude CVD death counts for each age/gender group by the
15

estimated number of people with CVD in that age/gender group (2019 population size from the
United States Census Bureau 23 multiplied by the American Heart Association’s 2016 CVD
prevalence estimates24).
TABLE 2. MORTALITY P ARAMETERS

Transition(s)

Calculation

Value(s)

Source

→ Background Mortality

All-Cause Mortality CVD-related Mortality

Appendix A
(Table 12)

All-Cause Mortality (Social
Security Administration),
CVD-related Mortality
(CDC WONDER)

Hospitalized, Waiting for
Appointment (Post
Emergency) or Short-Term
Post Hospitalization
Recovery → CVD Death

(Crude CVD death
counts/(Population
Size*CVD
Prevalence))*Multiplier

Appendix A
(Table 12),
Multipliers
(Table 5)

Crude CVD Death Counts
(CDC WONDER),
Population Size (2019
Census), CVD Prevalence
(AHA),

Waiting for Appointment
(“Silent” CVD) or LongTerm CVD Management →
CVD Death

Crude CVD death
counts/(Population
Size*CVD Prevalence)

Appendix A
(Table 12)

Crude CVD Death Counts
(CDC WONDER),
Population Size (2019
Census), CVD Prevalence
(AHA),

The remaining transition rates in this model (Table 3) were informed by Medicaid claims
data and values taken from published research and guidelines. Incidence of stroke, acute
myocardial infarction, angina, arrythmia, and other CVD symptoms and hospital admission,
hospital readmission, and provider appointment rates were pulled from the cohort of 2016
Tennessee Medicaid managed care beneficiaries (N = 1,669,258 members). The rate at which
patients moved out of the hospital and into short-term post hospitalization recovery was
informed by mean lengths of hospital stay for AMI and stroke in the United States. The
American Heart Association’s 2019 update to their annual Heart Disease and Stroke Statistics
report listed a mean rehabilitation length of stay for stroke of 14.6 days.25 The Healthcare Cost
16

and Utilization Project from the Agency for Healthcare Research and Quality reported an
average length of stay of 5.3 days in 2010.26 These values were averaged together to calculate the
transition rate parameter. The annual provider checkup rate during long-term CVD management
was taken from average office visit utilization for Medicaid beneficiaries with CVD in 2009
from the Kaiser Commission on Medicaid and the Uninsured.27
TABLE 3. OTHER MODEL P ARAMETERS

Transition(s)

Calculation

Value(s)

Source

Well → Hospitalized

Annual incident stroke rate +
Annual incident AMI rate

Appendix A
(Table 13)

Tennessee
Medicaid claims

Well → Waiting for
Appointment (“Silent”
CVD)

Annual incident angina rate +
Annual incident arrythmia rate +
Annual incident other CVD rate

Appendix A
(Table 13)

Tennessee
Medicaid claims

Waiting for Appointment
(“Silent” CVD) or LongTerm CVD Management
→ Hospitalized

Annual probability of CVD-related
hospitalization

Appendix A
(Table 14)

Tennessee
Medicaid claims

Short-Term Post
Hospitalization Recovery
→ Hospitalized

(30-day readmission after
emergency + 30-day readmission
after symptoms) * (365.25/30)

Appendix A
(Table 14)

Tennessee
Medicaid claims

Short-Term Post
Hospitalization Recovery
→ Waiting for
Appointment (Post
Emergency)

Annual probability of care with
CVD specialist due to worsening
symptoms

Appendix A
(Table 14)

Tennessee
Medicaid claims

Hospitalized → ShortTerm Post Hospitalization
Recovery

Average of mean length of hospital
stay AMI (5.3 days) + stroke (14.6
days)

9.95 days

Mean length
AMI (AHRQ),
Mean length
stroke (AHA)

Long-Term CVD
Management → Waiting
for Appointment (“Silent”
CVD)

Average number of office visits for
Medicaid beneficiaries with CVD in
2009 was 10.2

1/10.2

KFF
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Model Inputs – Network Adequacy Strategies
Two types of network adequacy standard strategies were explored in this model. First, the
maximum amount of time a Medicaid MCO enrollee would have to wait to see a provider after
initiating an appointment. The Legal Action Center’s 2020 report 28 was used to survey existing
or previously used standards to select wait times to be considered “short”, “medium”, and “long”
(Table 4). Colorado had the strictest quantitative criteria; Medicaid MCO enrollees had to be
given an appointment date within 7 calendar days of requesting primary care from a contracted
physician. Vermont had the most lenient quantitative criteria; Medicaid MCO enrollees had to be
given an appointment date within 90 days of requesting preventative care. All other states that
defined emergency or non-emergency quantitative criteria fell within this range. Wait times were
assumed to impact the transition rate from Waiting for Appointment (“Silent” CVD) and Waiting
for Appointment (Post-Emergency) to the Long-Term CVD Management state. Since the time an
individual spends with a provider during an appointment is likely a small fraction of one day, it
was considered negligible for the purposes of this model.
TABLE 4. APPOINTMENT WAIT TIME NETWORK A DEQUACY S TANDARD PARAMETERS

Strategy Name

Source

Value

Short

Colorado (primary care)

7 days

Medium

No specific state; chosen as a potential new strategy

45 days

Long

Vermont (preventive care)

90 days

Second, the time taken for an enrollee to arrive at a hospital due to distance was assumed
to impact the risk of mortality. The Legal Action Center’s 2020 report was again used to survey
existing or previously used standards to select travel times to be considered “none”, “short”, and
18

“long” (Table 5).29 Vermont had the most lenient quantitative criteria; Medicaid MCO enrollees
needed to receive major trauma treatment within 90 minutes of initiating care. Eight states
specified a 30-minute travel time maximum. As taken from research on acute myocardial
infarction in 2010, every 30 minutes of delay increases the annual mortality risk for an individual
by 7.5%.30 The calculated increased risk was multiplied by the annual rate of medical facility
mortality (Table 2) to calculate the high-risk death rate.
TABLE 5. TRAVEL TIME DELAY NETWORK ADEQUACY STANDARD PARAMETERS

Strategy Name

Description

Value

None

No specific state; chosen to depict no increased
mortality risk due to delay

0 minutes (0%
increased risk)

Short

California, Florida, Kentucky, Minnesota, New
Jersey, Oklahoma, Pennsylvania, Tennessee

30 minutes (7.5%
increased risk)

Long

Vermont (major trauma treatment)

90 minutes (22.5%
increased risk)

Model Inputs – Costs
To complete an analysis of health system cost burden under different network adequacy
standards, estimated cost values for events (hospital and provider visits) and annual existence in
a state were taken from published research (Table 6). Due to lack of access to data, these costs
were not stratified by age and gender and were taken from studies spanning the last 20 years. The
2012 Kaiser Family Foundation report called Medicaid and the Uninsured provided data on
average annual per capita spending on Medicaid beneficiaries with or without CVD.31 Nichols et
al. used patient data across health plans from the Kaiser Permanente Northwest CVD registry
(2000-2005) to calculate the average annual outpatient costs for patients with established CVD;
this value was used as the average cost burden for an individual in a recovery state in the
19

simulation model.32 Lump sum costs were taken from average hospitalization (stroke and heart
failure) costs33,34 and average provider visit events.35 It is assumed that individuals who die in
this model do not incur any more health care costs. This simulation model applies a discounting
method which weights costs incurred closer to the simulation start as more valuable than those
that occur farther in the future.36
TABLE 6. MODEL S TATE AND E VENT C OSTS

State/Event

Description

Cost

Source

Well (State)

Average annual per capita spending on
Medicaid beneficiaries without CVD
was $4,456 in 2009

$4,456/year

KFF

Hospitalized, Waiting
for Appointment
(States)

Average annual per capita spending on
Medicaid beneficiaries with CVD was
$9,694 in 2009

$9,694/year

KFF

In Recovery (States)

Total mean annual direct medical costs
for CVD patients ($18,953) *
Outpatient proportion (57.2%)
Assumed no economic burden for
death

$10,841.12/year

Nichols et al.

$0/year

N/A

Hospitalization (Event)

Average of cost of stroke (mean of
ischemic, hemorrhagic, or other
strokes ($23,415.33)) + cost of heart
failure ($14,631)

$19,023/event

Heart Failure
(Kilgore et al.),
Stroke (Wang
et al.)

Provider Visit (Event)

Average total payment for Medicaidcovered primary care checkups in
2014-15 was $106

$106/event

Biener and
Selden

CVD Death,
Background Mortality
(States)

Model Outputs
Various performance indicators were collected for each patient over the course of the
simulation. These included survival time (years), age at death (years), number of lifetime
hospital visits, number of lifetime provider visits, total time spent in recovery (years), total time
20

spent waiting for an appointment (years), lifetime healthcare costs ($), and lifetime healthcare
costs attributable to hospitalization ($). Cohort averages and 95% confidence intervals for each
of these indicators were reported for each strategy, along with the percent of CVD deaths that
occurred while in recovery and the percent of CVD deaths that occurred while hospitalized.

RESULTS/DISCUSSION
All Strategy Combination Outputs
All nine possible strategy combinations were run separately to allow for visual inspection
of “best” and “worst” strategies. As noted earlier, the “best” strategy is considered the one that
yields the largest mean survival time and oldest mean age at death for individuals with CVD.
The “worst” strategy is the one that yields the smallest mean survival time and youngest mean
age at death for individuals with CVD. Selected results are displayed in Table 7 through Table 8
(notable outcomes highlighted) and the full simulation output is presented in Appendix B.
TABLE 7. MEAN AGE AT DEATH (CVD)

Short Wait Time (7
days)

Medium Wait Time
(45 days)

Long Wait Time (90
days)

No Travel Delay (0
mins)

83.11 (82.39, 83.84)
years

83.79 (83.10, 84.47)
years

82.96 (82.24, 83.68)
years

Short Travel Delay
(30 mins)

82.92 (82.21, 83.62)
years

83.42 (82.73, 84.12)
years

83.24 (82.51, 83.98)
years

Long Travel Delay
(90 mins)

82.35 (81.58, 83.12)
years

82.94 (82.21, 83.67)
years

83.01 (82.31, 83.71)
years

After all strategy combinations were run, it was found that the strategy with a 45-day
appointment wait time and 0-minute travel time delay yielded the most favorable health
outcomes for individuals with CVD (Table 7); a mean age at death of 83.79 (83.10, 84.47) and a
21

mean survival time of 32.08 (31.09, 33.07). The least favorable outcomes occurred under the 7day appointment wait time and 90-minute travel delay strategy; a mean age at death of 82.35
(81.58, 83.12) and a mean survival time of 30.76 (29.73, 31.79). For individuals who develop
CVD who experience short or medium wait times, life expectancy decreases as travel time delay
increases. If hospitalized individuals experience a 90-minute travel delay, increasing
appointment wait time increases life expectancy. There were no other clearly discernable trends.
TABLE 8. MEAN AGE AT DEATH (NON-CVD)

Short Wait Time (7
days)

Medium Wait Time
(45 days)

Long Wait Time (90
days)

No Travel Delay (0
mins)

85.43 (85.20, 85.67)
years

85.33 (85.09, 85.57)
years

85.74 (85.50, 85.97)
years

Short Travel Delay
(30 mins)

85.59 (85.36, 85.83)
years

85.53 (85.30, 85.77)
years old

85.65 (85.42, 85.88)
years

Long Travel Delay
(90 mins)

85.37 (85.13, 85.61)
years

85.39 (85.15, 85.62)
years

85.30 (85.07, 85.54)
years

It must be noted that the life expectancy in the United States in 2019 was 78.8 years.37 In
the simulation results, CVD and non-CVD death mean age at death outcomes range from 82.35
(81.58, 83.12) to 83.79 (83.10, 84.47) and 85.30 (85.07, 85.54) to 85.74 (85.50, 85.97),
respectively. Although these results did align with the expectation that individuals with CVD live
shorter lives than those without CVD, individuals in the simulation model lived much longer
than they would have in reality. The histograms for CVD and non-CVD death were visually
inspected (Figure 2.) for anomalies and no oddities were found in the distributions. This
disparity is likely due to two concessions that were made when selecting data to inform mortality
parameters. First, mortality data for the low-income population was unavailable through
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Medicaid claims; Social Security Administration and CDC WONDER mortality data for the
general population were used instead. This may have inflated the simulated life expectancy as
studies have shown that lower income is associated with lower life expectancy. 38 Second, due to
unavailability of data, the 85 and older population was assumed to have the same CVD-related
mortality rates as the 80-84 age group. This may have overestimated the simulated life
expectancy for CVD death as it is probable that the 85 and older population would have higher
CVD mortality rates than the 80-84 age group, as evidenced by the continuous increase in agestratified CVD mortality rates (Table 12).
FIGURE 2. HISTOGRAMS OF P ATIENT AGE AT DEATH (CVD AND NON-CVD DEATHS )

Despite being the preferred strategy for CVD life expectancy, the medium appointment
wait time and no travel delay strategy did not yield the best outcomes for individuals who died of
non-CVD causes (Table 8). This group had the largest life expectancy under the long wait time
and no travel delay strategy at 85.74 years (85.50, 85.97). This result is peculiar; larger
appointment wait times were hypothesized to curtail lifespan for Medicaid recipients due to a
decline in care access. It is possible that this occurs because this simulation model only applies
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modified network adequacy standards to CVD-afflicted individuals. In reality, changes in
appointment wait times or travel times do not solely affect those with CVD—they impact care
accessibility across the full spectrum of health conditions, especially those that require high
levels of management and intervention. It would add an unmanageable amount of complexity to
amend the model’s structure and input parameters to account for this.
Table 9 outlines the proportion of each simulated cohort that died from CVD or nonCVD causes while waiting for an appointment with a provider. The results show that increasing
wait times increases this death percentage. This is likely because as wait times increase,
individuals in long-term recovery spend more time living and dying in the Waiting for
Appointment state as they do in the Long-Term CVD Management state. There are some other
trends in these results; increasing travel delay for those with medium wait times increases the
percentage of deaths that occur while waiting and increasing travel delay for those with long wait
times decreases this percentage. If reducing this statistic is the main goal of policymakers, the
best strategy would be the 7-day wait time and 30-minute travel delay strategy.
TABLE 9. PERCENT OF INDIVIDUALS WHO DIED W HILE W AITING FOR APPOINTMENT

Short Wait Time (7
days)

Medium Wait Time
(45 days)

Long Wait Time (90
days)

No Travel Delay (0
mins)

12.9%

43.14%

56.12%

Short Travel Delay
(30 mins)

12.84%

43.45%

55.95%

Long Travel Delay
(90 mins)

13.27%

43.92%

55.72%
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If having less CVD deaths occur in hospitals is the primary goal for policymakers, a 0min travel delay and 7-day wait time strategy would be the preferred network adequacy standard
strategy (Table 10). Under this strategy, 0.1678% of CVD deaths occur in a hospital, 83.22%
occur in recovery, and the remaining occur while waiting for an appointment with a provider. It
must be noted that a lower percentage of CVD deaths occurring in hospitals does not necessarily
indicate better population health outcomes; individuals may be dying from a CVD emergency
before they get to the hospital. Ideally, a lower percentage of deaths occurring in a hospital
means that CVD deaths are being shifted towards occurring in long-term recovery. In this
recovery state, individuals take medication and receive checkups frequently while living
relatively similar lifestyles to individuals who do not develop cardiovascular disease. Only one
trend is found in these outcome data; increasing travel time delay for individuals experiencing
medium wait times decreases the proportion of CVD deaths that occur in-hospital.
TABLE 10. PERCENT OF CVD DEATHS WHILE HOSPITALIZED

Short Wait Time (7
days)

Medium Wait Time
(45 days)

Long Wait Time (90
days)

No Travel Delay (0
mins)

0.1678%

0.8143%

0.4975%

Short Travel Delay
(30 mins)

0.4902%

0.4823%

1.0256%

Long Travel Delay
(90 mins)

0.9317%

0.3328%

0.9756%

This study focuses only on costs borne by Medicaid. Table 11 outlines the average cost
burden per person that Medicaid patients accumulate over their lifetime under different network
adequacy standard strategies. The most expensive strategy is the 0-minute travel delay and 7-day
appointment wait time strategy at $2,126,374 (2,099,855, 2,152,893) and the least expensive
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strategy is the 90-minute travel delay and 90-day appointment wait time strategy at $895,665
(884,272, 907,059). This is not an unexpected result; stricter network adequacy standards lead to
more interactions with the health care system. Each of these interactions (e.g. hospitalization,
provider visit) have costs associated with them—costs that individuals who have died or are not
accessing care do not have to bear. Future studies of the economic burden resulting from network
adequacy standard changes should run cost-benefit analyses and incorporate data on quality of
life, lost productivity, the value of statistical life lost,39 and emotional harm into the simulation.
TABLE 11. HEALTH SYSTEM C OST B URDEN (DISCOUNTED )

Short Wait Time (7
days)

Medium Wait Time (45
days)

Long Wait Time (90
days)

No Travel Delay
(0 mins)

$2,126,374 (2,099,855,
2,152,893)

$1,243,781 (1,228,372,
1,259,189)

$905,448 (894,189,
916,707)

Short Travel
Delay (30 mins)

$2,120,245 (2,093,932,
2,146,557)

$1,256,276 (1,240,837,
1,271,715)

$906,935 (895,582,
918,288)

Long Travel
Delay (90 mins)

$2,096,170 (2,069,591,
2,122,749)

$1,244,368 (1,229,009,
1,259,728)

$895,665 (884,272,
907,059)

Comparison of Expected “Best” vs. “Worst” Strategies
The strategies expected to be the “best” (7-day appointment wait times and no travel
delay) and “worst” (90-day appointment wait times and 90-min travel delay for emergencies)
were run in comparison to one another. Statistically significant differences were found for time
spent in recovery, time spent waiting for an appointment, number of provider visits, and
healthcare system cost burden. Statistically significant differences were not found for mean
survival time (CVD death or non-CVD death), mean age at death (CVD death or non-CVD
death), number of hospital visits, and costs attributable to hospitalization. Graphical
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representations of the outcome comparisons that yielded statistical significance are presented in
Figure 3.
FIGURE 3. C OMPARISON OF E XPECTED B EST VS. W ORST STRATEGIES – S TATISTICALLY SIGNIFICANT DIFFERENCES

The top left and bottom right panels contain comparative histograms of provider visits
and individual costs, respectively, under these two strategies. These results indicate that shorter
appointment wait times and no travel delay led to greater utilization of the healthcare system
through significantly larger quantities of provider visits. Since there was no statistically
significant increase in hospitalizations, the increase in costs per individual per lifetime are likely
attributable to this increase in provider visits. The top right and bottom left panels contain
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comparative histograms of time spent in recovery and waiting for appointment. These histograms
seem to be inverses of one another; as appointment wait times increase, individuals spend more
of their long-term recovery actively waiting for an appointment for a checkup with a provider.
Limitations
Since major assumptions and simplifications were made to keep this simulation
manageable, this model may not fully capture the complexities of the ways in which the natural
history of cardiovascular disease and the healthcare system interact. First, it would be beneficial
to consult with cardiovascular disease experts to ensure accuracy in the assumed natural history
of cardiovascular disease and treatment practices. It is possible that the long-term manifestations
of the two CVD pathways specified in this model (sudden cardiac emergency or “silent” CVD)
require starkly different methods of treatment—this model assumes identical treatment after
individuals who experience sudden cardiac emergency recover. In addition, Medicaid is not the
only government-run social safety net program that aids the low-income population; certain
individuals are dually eligible to enroll in Medicaid and Medicare when they turn 65. 40 It would
add value to this model to incorporate dual enrollees and investigate how access to further
services under Medicare alters health outcomes and alleviates some of the economic burden on
Medicaid.
Second, the ways in which network adequacy standards are applied in this model may not
be wholly representative of reality. Minimum travel time standards are typically defined for the
broad array of provider and hospital visit types. In this model, due to the availability of minimal
data on the impact of travel on CVD health, travel time is only applied in the form of a delay en
route to a hospital in the case of emergency. Also, appointment wait time standards are defined
as allowed maximums. Data on the actual distributions of wait times were unavailable (e.g. a 4528

day wait time does not necessarily mean an individual will wait the full 45 days in all scenarios)
and further models should attempt to incorporate this nuance. Third, most of the parameter data
came from the 2019 Tennessee Medicaid MCO cohort but data were also taken, as needed, from
research that investigated other populations. As previously mentioned, the mortality and cost
data, length of hospital stays, and average number of provider visits used in this study were taken
from research on the general population that spanned the years 2000-2019. Although, parameters
were taken from reputable sources, this overall lack of consistency across localities, income
levels, and time periods may have dampened the quality and accuracy of the study results.
Fourth, more robust calibration must be done to alleviate existing doubts on the internal
validity of the simulation results. As seen in the cohort means produced in the simulation results
(Appendix B), individuals are estimated to live between 82.35 (81.58, 83.12) to 83.79 (83.10,
84.47) years, visit a hospital 9.88 (9.37, 10.39) to 10.67 (10.13, 11.21) times in their lives, visit a
provider 60.59 (59.70, 61.48) to 180.59 (177.97, 183.21) times in their lives, and cost Medicaid
$895,665 (884,272, 907,059) to $2,126,374 (2,099,855, 2,152,893). Medicaid populationspecific data on life expectancy, lifetime number of hospital or provider visits, and lifetime
healthcare system cost burdens are needed to confirm the realness and accuracy of these model
output ranges. Additionally, a big indicator of model inaccuracy is that approximately 6-7% of
the cohort in this model die of CVD; this is starkly different from the CDC’s estimate that 1 in 4
deaths are due to CVD.41

CONCLUSION
This is the first study done to analyze the impact of state-level network adequacy
standards on health through the usage of a continuous-time Markov model. The goals of this
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project were to formulate appropriate simulation modeling methods and provide a strategy
recommendation to policymakers. After all strategy combinations were run, it was found that the
strategy with a 45-day appointment wait time and 0-minute travel time delay yielded the most
favorable health outcomes for individuals with CVD (Table 7); a mean age at death of 83.79
(83.10, 84.47) and a mean survival time of 32.08 (31.09, 33.07). When the strategies expected to
be the “best” (7-day appointment wait times and no travel delay) and “worst” (90-day
appointment wait times and 90-min travel delay for emergencies) were run in comparison to one
another, statistically significant differences were found for time spent in recovery or waiting for
an appointment, provider visit quantity, and healthcare system cost burden. Statistically
significant differences were not found for life expectancy, hospital visit quantity, and costs
attributable to hospitalization.
These results are preliminary and should not be used to make policy decisions until
further complexities are incorporated and calibration is completed. Such model modifications
may include updating mortality rate parameters to be representative of low-income populations,
taking cost data directly from Medicaid claims, consulting with cardiovascular disease experts to
ensure accuracy natural history of CVD and treatment regimen assumptions, expanding
definition of economic burden, and running cost-benefit analyses. The third type of network
adequacy standard, provider characteristics, went unexplored in this study; a discrete time model
would be best suited for investigating the impact of changing provider-to-enrollee ratios and/or
hours of operation on CVD outcomes. This inaugural research attempt is a step towards settling
the network adequacy standard policy debate and imbuing some level of standardization within
Medicaid MCOs across the nation.
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APPENDIX A – Detailed Parameter Tables
TABLE 12. AGE - AND G ENDER-STRATIFIED MORTALITY R ATES IN 2019

Age Group

Gender

Background
Mortality

Total CVD
Death

CVD Death
Medical Facility

CVD Death NonMedical Facility

40-44

F

0.001596

0.000282

0.000118

0.000073

40-44

M

0.002828

0.000578

0.000196

0.000160

45-49

F

0.002332

0.000458

0.000188

0.000130

45-49

M

0.003831

0.000996

0.000342

0.000285

50-54

F

0.003529

0.000745

0.000280

0.000241

50-54

M

0.005808

0.001689

0.000532

0.000530

55-59

F

0.005425

0.001181

0.000469

0.000424

55-59

M

0.009047

0.002686

0.000843

0.000939

60-64

F

0.008006

0.001851

0.000452

0.000447

60-64

M

0.013248

0.004057

0.000914

0.001084

65-69

F

0.011158

0.002748

0.000563

0.000589

65-69

M

0.018280

0.005681

0.001062

0.001267

70-74

F

0.017892

0.004569

0.000722

0.000837

70-74

M

0.026249

0.008095

0.001195

0.001436

75-79

F

0.029837

0.008093

0.000836

0.001121

75-79

M

0.042159

0.012814

0.001202

0.001564

80-84

F

0.051658

0.01565

0.003311

0.005965

80-84

M

0.069190

0.022111

0.005548

0.009022

85-89

F

0.091587

0.01565

0.003450

0.008694

85-89

M

0.117771

0.022111

0.004720

0.010427

90-94

F

0.159491

0.01565

0.002708

0.010153

90-94

M

0.197287

0.022111

0.002759

0.008995

95-99

F

0.249466

0.01565

0.001118

0.006030
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95-99

M

0.297897

0.022111

0.000868

0.003811

100+

F

0.336563

0.01565

0.000194

0.001582

100+

M

0.383560

0.022111

0.000096

0.000576

TABLE 13. AGE - AND G ENDER-STRATIFIED CVD SYMPTOM INCIDENCE R ATES IN 2019

Age Gender
Group

Stroke

AMI

Angina

Arrythmia

Other CVD

40-44

F

0.0016

0.0039

0.0041

0.007

0.0511

40-44

M

0.0019

0.006

0.0041

0.0052

0.0472

45-49

F

0.0029

0.007

0.0067

0.0072

0.0677

45-49

M

0.0035

0.0101

0.008

0.0056

0.0651

50-54

F

0.0053

0.0122

0.0102

0.0069

0.0896

50-54

M

0.0052

0.015

0.0105

0.0065

0.0866

55-59

F

0.0083

0.0188

0.0137

0.0096

0.1182

55-59

M

0.0093

0.0245

0.0145

0.0108

0.1199

60-64

F

0.0111

0.0262

0.014

0.0104

0.1422

60-64

M

0.0129

0.0303

0.0143

0.0121

0.1569

65-69

F

0.014

0.0338

0.0156

0.013

0.1566

65-69

M

0.0158

0.043

0.0152

0.016

0.1912

70-74

F

0.0051

0.0158

0.0055

0.0058

0.0747

70-74

M

0.0055

0.02

0.0054

0.0055

0.0861

75-79

F

0.0024

0.0102

0.0026

0.0017

0.0383

75-79

M

0.0016

0.011

0.0027

0.0019

0.0421

80-84

F

0.002

0.0111

0.0016

0.0023

0.036

80-84

M

0.0025

0.0114

0.0022

0.0018

0.0392

85-89

F

0.0019

0.0125

0.002

0.0027

0.0379

85-89

M

0.0013

0.0124

0.0023

0.0023

0.034
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90-94

F

0.0013

0.0145

0.0013

0.0038

0.0246

90-94

M

0.0011

0.0143

0.0011

0.0032

0.0328

95-99

F

0.0004

0.0106

0.0002

0.0015

0.0193

95-99

M

0.0022

0.0099

0.0011

0.0011

0.032

100+

F

0.0008

0.0105

0.0016

0.0012

0.0141

100+

M

0

0.0062

0

0

0.0156

TABLE 14. AGE - AND G ENDER-STRATIFIED HOSPITALIZATION AND CVD S PECIALIST VISIT RATES IN 2019

Age Group

Gender

Probability of
CVD-related
Hospitalization

30-day
Readmission
after Emergency

30-day
Readmission
after Symptoms

Probability of
care with
CVD specialist

40-44

F

0.0023

0.2861

0.2727

0.1163

40-44

M

0.004

0.3592

0.2507

0.1146

45-49

F

0.0037

0.3031

0.2516

0.1658

45-49

M

0.0068

0.3322

0.2477

0.1568

50-54

F

0.0057

0.3537

0.2473

0.2097

50-54

M

0.0081

0.4296

0.2402

0.1886

55-59

F

0.0087

0.342

0.2471

0.2499

55-59

M

0.0132

0.3952

0.2504

0.2258

60-64

F

0.011

0.3553

0.245

0.2762

60-64

M

0.0164

0.3452

0.2577

0.2709

65-69

F

0.0122

0.4045

0.2283

0.2937

65-69

M

0.0203

0.3551

0.2375

0.3099

70-74

F

0.0038

0.2248

0.1804

0.1266

70-74

M

0.0072

0.3568

0.2132

0.1319

75-79

F

0.0013

0.2258

0.1037

0.0601

75-79

M

0.0029

0.2069

0.1229

0.0559
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80-84

F

0.0013

0.2162

0.0827

0.0536

80-84

M

0.0007

0.0769

0.0893

0.052

85-89

F

0.0007

0.0196

0.1366

0.0472

85-89

M

0.0013

0.1667

0.0714

0.0392

90-94

F

0.0007

0.1212

0.0709

0.0315

90-94

M

0.0005

0

0.0947

0.0396

95-99

F

0.0004

0.3

0.0741

0.0266

95-99

M

0.0011

0

0.0841

0.0343

100+

F

0.0004

0

0.0545

0.0164

100+

M

0

0

0

0.0156

34

APPENDIX B – Simulation Results for All Strategies
SHORT Wait Times, NONE Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 31.56 (30.59, 32.54)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.59 (29.27, 29.91)
Estimate of mean age at death (CVD death) and 95% confidence interval: 83.11 (82.39, 83.84)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.43 (85.20, 85.67)
% of individuals who died while waiting for appointment: 0.129
% CVD deaths that occurred while in recovery: 0.8322147651006712
% CVD deaths that occurred while hospitalized: 0.0016778523489932886
Estimate of number of hospital visits and 95% confidence interval: 10.44 (9.90, 10.98)
Estimate of number of provider visits and 95% confidence interval: 180.59 (177.97, 183.21)
Estimate of time spent in recovery and 95% confidence interval: 18.86 (18.61, 19.12)
Estimate of time spent waiting for appointment and 95% confidence interval: 3.47 (3.42, 3.52)
Estimate of discounted cost and 95% confidence interval: 2,126,374 (2,099,855, 2,152,893)
Estimate of hospitalization cost and 95% confidence interval: 125,407 (119,128, 131,686)

SHORT Wait Times, SHORT Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 31.33 (30.36, 32.30)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.68 (29.36, 30.00)
Estimate of mean age at death (CVD death) and 95% confidence interval: 82.92 (82.21, 83.62)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.59 (85.36, 85.83)
% of individuals who died while waiting for appointment: 0.1284
% CVD deaths that occurred while in recovery: 0.8202614379084967
% CVD deaths that occurred while hospitalized: 0.004901960784313725
Estimate of number of hospital visits and 95% confidence interval: 10.33 (9.80, 10.86)
Estimate of number of provider visits and 95% confidence interval: 180.03 (177.42, 182.63)
Estimate of time spent in recovery and 95% confidence interval: 18.80 (18.55, 19.06)
Estimate of time spent waiting for appointment and 95% confidence interval: 3.45 (3.40, 3.50)
Estimate of discounted cost and 95% confidence interval: 2,120,245 (2,093,932, 2,146,557)
Estimate of hospitalization cost and 95% confidence interval: 123,753 (117,611, 129,894)
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SHORT Wait Times, LONG Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 30.76 (29.73, 31.79)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.24 (28.92, 29.56)
Estimate of mean age at death (CVD death) and 95% confidence interval: 82.35 (81.58, 83.12)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.37 (85.13, 85.61)
% of individuals who died while waiting for appointment: 0.1327
% CVD deaths that occurred while in recovery: 0.8229813664596274
% CVD deaths that occurred while hospitalized: 0.009316770186335404
Estimate of number of hospital visits and 95% confidence interval: 10.46 (9.92, 10.99)
Estimate of number of provider visits and 95% confidence interval: 177.24 (174.63, 179.86)
Estimate of time spent in recovery and 95% confidence interval: 18.56 (18.30, 18.82)
Estimate of time spent waiting for appointment and 95% confidence interval: 3.40 (3.35, 3.45)
Estimate of discounted cost and 95% confidence interval: 2,096,170 (2,069,591, 2,122,749)
Estimate of hospitalization cost and 95% confidence interval: 127,177 (120,815, 133,540)

MEDIUM Wait Times, NONE Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 32.08 (31.09, 33.07)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.40 (29.08, 29.72)
Estimate of mean age at death (CVD death) and 95% confidence interval: 83.79 (83.10, 84.47)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.33 (85.09, 85.57)
% of individuals who died while waiting for appointment: 0.4314
% CVD deaths that occurred while in recovery: 0.4723127035830619
% CVD deaths that occurred while hospitalized: 0.008143322475570033
Estimate of number of hospital visits and 95% confidence interval: 10.32 (9.79, 10.85)
Estimate of number of provider visits and 95% confidence interval: 94.87 (93.49, 96.25)
Estimate of time spent in recovery and 95% confidence interval: 10.48 (10.33, 10.62)
Estimate of time spent waiting for appointment and 95% confidence interval: 11.72 (11.55, 11.89)
Estimate of discounted cost and 95% confidence interval: 1,243,781 (1,228,372, 1,259,189)
Estimate of hospitalization cost and 95% confidence interval: 123,970 (117,762, 130,178)
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MEDIUM Wait Times, SHORT Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 32.17 (31.20, 33.14)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.45 (29.13, 29.77)
Estimate of mean age at death (CVD death) and 95% confidence interval: 83.42 (82.73, 84.12)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.53 (85.30, 85.77)
% of individuals who died while waiting for appointment: 0.4345
% CVD deaths that occurred while in recovery: 0.4533762057877814
% CVD deaths that occurred while hospitalized: 0.00482315112540193
Estimate of number of hospital visits and 95% confidence interval: 10.57 (10.03, 11.11)
Estimate of number of provider visits and 95% confidence interval: 95.41 (94.02, 96.80)
Estimate of time spent in recovery and 95% confidence interval: 10.58 (10.43, 10.72)
Estimate of time spent waiting for appointment and 95% confidence interval: 11.77 (11.60, 11.94)
Estimate of discounted cost and 95% confidence interval: 1,256,276 (1,240,837, 1,271,715)
Estimate of hospitalization cost and 95% confidence interval: 128,861 (122,440, 135,282)

MEDIUM Wait Times, LONG Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 31.16 (30.11, 32.21)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.52 (29.21, 29.84)
Estimate of mean age at death (CVD death) and 95% confidence interval: 82.94 (82.21, 83.67)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.39 (85.15, 85.62)
% of individuals who died while waiting for appointment: 0.4392
% CVD deaths that occurred while in recovery: 0.4492512479201331
% CVD deaths that occurred while hospitalized: 0.0033277870216306157
Estimate of number of hospital visits and 95% confidence interval: 9.88 (9.37, 10.39)
Estimate of number of provider visits and 95% confidence interval: 95.31 (93.92, 96.69)
Estimate of time spent in recovery and 95% confidence interval: 10.48 (10.34, 10.63)
Estimate of time spent waiting for appointment and 95% confidence interval: 11.75 (11.58, 11.92)
Estimate of discounted cost and 95% confidence interval: 1,244,368 (1,229,009, 1,259,728)
Estimate of hospitalization cost and 95% confidence interval: 120,626 (114,550, 126,702)

37

LONG Wait Times, NONE Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 30.85 (29.82, 31.88)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.91 (29.59, 30.23)
Estimate of mean age at death (CVD death) and 95% confidence interval: 82.96 (82.24, 83.68)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.74 (85.50, 85.97)
% of individuals who died while waiting for appointment: 0.5612
% CVD deaths that occurred while in recovery: 0.3101160862354892
% CVD deaths that occurred while hospitalized: 0.004975124378109453
Estimate of number of hospital visits and 95% confidence interval: 10.62 (10.10, 11.14)
Estimate of number of provider visits and 95% confidence interval: 61.61 (60.72, 62.50)
Estimate of time spent in recovery and 95% confidence interval: 7.30 (7.19, 7.40)
Estimate of time spent waiting for appointment and 95% confidence interval: 15.22 (15.00, 15.44)
Estimate of discounted cost and 95% confidence interval: 905,448 (894,189, 916,707)
Estimate of hospitalization cost and 95% confidence interval: 128,241 (122,046, 134,436)

LONG Wait Times, SHORT Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 31.52 (30.46, 32.57)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.61 (29.30, 29.93)
Estimate of mean age at death (CVD death) and 95% confidence interval: 83.24 (82.51, 83.98)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.65 (85.42, 85.88)
% of individuals who died while waiting for appointment: 0.5595
% CVD deaths that occurred while in recovery: 0.3282051282051282
% CVD deaths that occurred while hospitalized: 0.010256410256410256
Estimate of number of hospital visits and 95% confidence interval: 10.67 (10.13, 11.21)
Estimate of number of provider visits and 95% confidence interval: 61.37 (60.48, 62.26)
Estimate of time spent in recovery and 95% confidence interval: 7.23 (7.13, 7.34)
Estimate of time spent waiting for appointment and 95% confidence interval: 15.12 (14.91, 15.34)
Estimate of discounted cost and 95% confidence interval: 906,935 (895,582, 918,288)
Estimate of hospitalization cost and 95% confidence interval: 129,102 (122,743, 135,461)
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LONG Wait Times, LONG Travel Time Delay
Estimate of mean survival time (CVD death) and 95% confidence interval: 31.42 (30.44, 32.39)
Estimate of mean survival time (non-CVD death) and 95% confidence interval: 29.20 (28.88, 29.52)
Estimate of mean age at death (CVD death) and 95% confidence interval: 83.01 (82.31, 83.71)
Estimate of mean age at death (non-CVD death) and 95% confidence interval: 85.30 (85.07, 85.54)
% of individuals who died while waiting for appointment: 0.5572
% CVD deaths that occurred while in recovery: 0.3073170731707317
% CVD deaths that occurred while hospitalized: 0.00975609756097561
Estimate of number of hospital visits and 95% confidence interval: 10.47 (9.93, 11.01)
Estimate of number of provider visits and 95% confidence interval: 60.59 (59.70, 61.48)
Estimate of time spent in recovery and 95% confidence interval: 7.17 (7.06, 7.28)
Estimate of time spent waiting for appointment and 95% confidence interval: 14.96 (14.74, 15.17)
Estimate of discounted cost and 95% confidence interval: 895,665 (884,272, 907,059)
Estimate of hospitalization cost and 95% confidence interval: 126,073 (119,739, 132,406)
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